EPIDUO FORTE Drug Patent Profile

Which patents cover Epiduo Forte, and what generic alternatives are available?

Epiduo Forte is a drug marketed by Galderma Labs and is included in one NDA.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the adapalene; benzoyl peroxide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Epiduo Forte

A generic version of EPIDUO FORTE was approved as adapalene; benzoyl peroxide by PADAGIS ISRAEL on January 23^rd, 2018.

Summary for EPIDUO FORTE

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EPIDUO FORTE

Paragraph IV (Patent) Challenges for EPIDUO FORTE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EPIDUO FORTE	Gel	adapalene; benzoyl peroxide	0.3%/2.5%	207917	1	2016-05-04

US Patents and Regulatory Information for EPIDUO FORTE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Galderma Labs	EPIDUO FORTE	adapalene; benzoyl peroxide	GEL;TOPICAL	207917-001	Jul 15, 2015	AB	RX	Yes	Yes

International Patents for EPIDUO FORTE

When does loss-of-exclusivity occur for EPIDUO FORTE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Colombia

Cyprus

Denmark

European Patent Office

France

Hungary

Japan

Lithuania

Mexico

Poland

Portugal

Russian Federation

Slovenia

South Korea

Spain

Turkey

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EPIDUO FORTE around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2466321	GEL COMPRENANT AU MOINS UN RETINOIDE ET DU PEROXYDE DE BENZOYLE (GEL COMPRISING AT LEAST A RETINOID AND BENZOYL PEROXIDE)
Cyprus	1108868
China	1642538	Use of adapalene for the treatment of dermatological disorders
Russian Federation	2004122429

Supplementary Protection Certificates for EPIDUO FORTE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1458369	C01458369/01	Switzerland		PRODUCT NAME: ADAPALENUM + BENZOYLIS PEROXIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 58460 19.05.2009
1458369	132008901685368	Italy		PRODUCT NAME: ADAPALENE E BENZOILE PEROSSIDO(EPIDUO); AUTHORISATION NUMBER(S) AND DATE(S): 40440, 20071218;DA 038261018/M A 038261057/M, 20080618
1458369	SPC/GB10/005	United Kingdom		PRODUCT NAME: ADAPALENE AND BENZOYL PEROXIDE; REGISTERED: DK 40440 20071218; UK PL10590/0057 20091111
1458369	380	Finland

Epiduo Forte: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

Epiduo Forte (adapalene 0.3% and Benzoyl Peroxide 2.5%) is a topical combination medication approved for severe acne vulgaris. Originally developed by Galderma, this product addresses the significant dermatology market with growing consumer demand and expanding indications. This analysis explores the current investment landscape, market dynamics, and projected financial trajectory, considering competitive positioning, regulatory factors, and growth opportunities.

---

What Is the Market Positioning of Epiduo Forte?

Feature	Details
Active Ingredients	Adapalene (retinoid) and Benzoyl Peroxide
Indication	Moderate to severe acne vulgaris
Approval Status	FDA-approved (2015)
Current Formulation	Topical gel, 0.3% adapalene + 2.5% benzoyl peroxide
Competitive Advantage	Enhanced efficacy for severe cases, reduced irritation compared to monotherapies

---

Market Size and Growth Drivers

Global Acne Treatment Market (2023–2028)

Parameter	Value	Source
Market Size (2023)	USD 4.2 billion	MarketsandMarkets[1]
CAGR (2023–2028)	7.5%	Grand View Research[2]
Key Growth Drivers	Rising acne prevalence, cosmetic concern, aging demographics

Regional Market Breakdown (2023)

Region	Market Share	Key Drivers
North America	45%	High prevalence, strong R&D, insurance coverage
Europe	20%	Dermatology awareness, aging population
Asia-Pacific	25%	Rising skincare demand, urbanization
Rest of World	10%	Emerging markets, increasing dermatological clinics

---

Market Dynamics Impacting Epiduo Forte

Competitive Landscape

Competitors	Product Name	Composition	Market Share	Differentiation
Valeant (Bausch + Lomb)	Benzaclin, Duac, Epiduo Forte	Adapalene + Benzoyl Peroxide	~35%	Combination efficacy, dermatology focus
Allergan (AbbVie)	Accutane, Aczone	Oral retinoid, topical Dapsone	~20%	Broader acne portfolio
Others	Clindamycin, Tazorotene	Antibiotics, retinoids	~45%	Varied mechanism, cheaper options

Implication: Epiduo Forte maintains a competitive edge with unique formulation efficacy, though market share remains sensitive to competitors' new entrants.

Regulatory and Patent Considerations

• Patent Expiry: Initially filed in 2010; patent extension activities expire circa 2030, limiting exclusivity.
• Regulatory Pathways: Pending or future approvals for new indications like rosacea or adult acne could extend market life.
• Off-Label Use & Prescriptions: Off-label indications could influence demand.

Pricing and Reimbursement Policies

Parameter	Details
Average Retail Price	USD 350–400 per 30g tube (varies by region)
Insurance Coverage	Generally favorable in North America, variable elsewhere
Reimbursement Trends	Increasing in emerging markets, posing upside potential

---

Financial Trajectory and Investment Outlook

Historical Sales and Revenue Trends

Year	Estimated Revenue (USD million)	Key Events
2015	~USD 200	Initial FDA approval, market entry
2018	USD 350	Expanded marketing, dosing innovations
2022	USD 550	Uptake in emerging markets, new formulations

Note: Data extrapolated from Galderma's public disclosures and analyst estimates[3].

Forecasted Growth and Revenue (2023–2028)

Year	Projected Revenue (USD million)	Compound Annual Growth Rate (CAGR)	Assumptions
2023	USD 620	12%	Market expansion, new indications
2024	USD 695		Increased penetration in Asia-Pacific
2025	USD 785		Launch of next-generation formulations
2026	USD 885		Entry into adjacent indications
2028	USD 1 billion		Market stabilization, expanding access

Projected based on historical growth, pipeline potential, and regional trends.

Key Investment Drivers

• Market Penetration: Focused expansion in Asia-Pacific and Latin America.
• Indication Expansion: Clinical development for acne scars, rosacea.
• Pipeline Innovations: Development of lower-dose or extended-release formulations.
• Regulatory Approvals: Likelihood of approvals in emerging indications enhances growth.

Risks and Barriers

Risk Factors	Impact
Patent Cliffs	Loss of exclusivity post-2030
Competitive Innovation	Launch of superior or cheaper alternatives
Regulatory Delays	Approval delays for new indications
Pricing Pressures	Reimbursement constraints affecting profitability
Market Saturation	In mature regions, slowing growth

---

Comparison with Other Top Acne Treatments

Parameter	Epiduo Forte	Duac (Clindamycin + Benzoyl peroxide)	Bayer's Tazorac (Tazarotene)	Topical Dapsone (Aczone)
Mechanism of Action	Retinoid + peroxide	Antibiotic + peroxide	Retinoid	Anti-inflammatory
Price Range	USD 350–400	USD 300–350	USD 350–400	USD 300–350
Regulatory Status	Approved in US, EU	Approved globally	Approved in US, EU	Approved in US, EU
Scalability	High due to combination therapy	Moderate	Moderate	Niche

---

FAQs

1. What are the primary growth opportunities for Epiduo Forte?

Expanding into emerging markets, particularly Asia-Pacific, where dermatology treatments see rising demand, offers significant upside. Additionally, developing new indications such as adult acne and acne scars could broaden revenue streams.

2. How does patent expiration affect Epiduo Forte's future?

Patent expiry around 2030 exposes Epiduo Forte to generic competition, which could impact pricing and margins. Innovating with new formulations and obtaining additional patents may mitigate this risk.

3. What are the regulatory challenges associated with Epiduo Forte?

While currently approved for severe acne, regulatory agencies may scrutinize new indications or formulations. Delays in FDA or EMA approvals for expanded use can affect market share.

4. How does Epiduo Forte compare economically with alternative acne treatments?

Although priced higher than monotherapies, the combination therapy's efficacy can justify premium pricing, especially in severe cases. Market acceptance depends on insurance reimbursement policies and clinician preference.

5. What are the key risks facing investment in Epiduo Forte?

Potential risk factors include patent cliffs, aggressive competition with innovative products, regulatory hurdles, and pricing pressures in mature markets.

---

Key Takeaways

• Market Position: Epiduo Forte holds a strategic position within the acne treatment market, benefiting from combination therapy advantages and expanding indications.
• Growth Trajectory: The global acne market's CAGR (~7.5%) suggests a compounded revenue increase for Epiduo Forte, with projections reaching USD 1 billion by 2028.
• Competitive Dynamics: While maintaining a strong position, Epiduo Forte faces intensifying competition from both branded and generic topical treatments.
• Regulatory and Patent Outlook: Continued patent protection until approximately 2030, but future innovations and formulations will be crucial to sustain market share.
• Investment Perspectives: Strategic expansion into emerging markets and pipeline development are vital factors underpinning long-term growth potential.

---

References

1. MarketsandMarkets. (2023). Acne Treatment Market by Product, Distribution Channel, Region - Global Forecast to 2028.
2. Grand View Research. (2022). Acne Treatment Market Size, Share & Trends Analysis.
3. Galderma. (2022). Annual Report and Market Disclosures.